Core Insights - Biogen and City Therapeutics have announced a strategic collaboration to develop novel RNA interference (RNAi) therapies, combining Biogen's drug development expertise with City Therapeutics' RNAi engineering technologies [1][2][3] - The collaboration will initially focus on a target related to central nervous system diseases, utilizing advanced drug delivery technologies for systemic administration [2][3] - City Therapeutics will receive $46 million, including a $16 million upfront payment and a $30 million investment, with potential milestone payments of up to $1 billion based on development success [3] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to deliver new medicines and create shareholder value [4] - City Therapeutics is a biopharmaceutical company specializing in next-generation RNAi technologies, aiming to expand the therapeutic reach of RNAi-based medicines [6]

Core Insights - Silexion Therapeutics is pioneering RNA interference (RNAi) therapies targeting KRAS-driven cancers, which are notoriously difficult to treat with traditional methods [2][3] - The lead candidate, SIL204, has shown promising preclinical results in reducing tumor growth and metastasis across various cancer types, including pancreatic, colorectal, and lung cancers [2][5] Technological Platform - Silexion's technology targets KRAS mutations at the genetic level, differing from conventional small molecule inhibitors, aiming to prevent oncogenic protein production [4] - SIL204 can target multiple KRAS mutations, which are prevalent in various cancers: approximately 90% in pancreatic cancers, 45% in colorectal cancers, and 35% in non-squamous non-small-cell lung cancers [5] Preclinical Developments - A significant milestone was reached in March 2025 with the completion of studies using orthotopic pancreatic cancer models, providing a more accurate representation of cancer progression [6] - SIL204 demonstrated notable efficacy in reducing tumor cell numbers across different pancreatic cancer cell lines, indicating a nuanced understanding of therapeutic interventions [7] Strategic Approach - Silexion focuses on two primary drug delivery methods: systemic delivery for metastatic progression and intratumoral delivery for primary tumors, collaborating with Catalent to enhance formulation and manufacturing processes [8] - The company's research extends beyond pancreatic cancer, exploring applications in colorectal and lung cancers, reflecting a comprehensive understanding of KRAS-driven malignancies [9] The Road Ahead - Silexion's development roadmap includes continued preclinical studies, toxicology and pharmacodynamic investigations, potential regulatory submissions, and plans to initiate human clinical trials in the first half of 2026 [10] - The scientific community is closely monitoring Silexion's progress, as successful outcomes could significantly impact cancer therapeutics and precision oncology [11]

Core Insights - Silexion Therapeutics is advancing its next-generation RNA interference (RNAi) therapeutic candidate, SIL204, targeting KRAS-driven cancers beyond pancreatic cancer, with treatment markets estimated at over $30 billion annually [1][3]. Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNAi therapies for solid tumors driven by KRAS mutations, which are prevalent in various cancers [4]. - The company's first-generation product, LODER™, has shown promising results in Phase 2 trials for non-resectable pancreatic cancer [4]. Study Details - The completed preclinical studies evaluated SIL204 in cancer cell lines with KRAS mutations, including colorectal cancer (GP2D), lung cancer (A427), and pancreatic cancer (Panc-1), chosen for their high prevalence of KRAS mutations and significant unmet medical needs [2][3]. - KRAS mutations are found in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-squamous non-small-cell lung cancers, highlighting the potential market for SIL204 [3]. Future Prospects - The completion of the expanded preclinical evaluation is seen as a significant milestone for the SIL204 development program, with expectations for positive results that could broaden the company's development strategy [3].

Core Insights - Silexion Therapeutics Corp. has made significant advancements in its preclinical pipeline for SIL204, demonstrating efficacy against both primary tumors and metastases in orthotopic models, which could represent a paradigm shift in treating KRAS-driven cancers [1][2] - The company has strengthened its financial position by raising over $9 million in gross funds during Q1 2025, enhancing its ability to advance its clinical development pipeline [1][2] Recent Milestones & Business Highlights - Positive data from orthotopic pancreatic cancer models showed that SIL204 reduced primary tumor growth by approximately 70% in the AsPC-1 model and 80% in the BxPC-3 model by day 28, along with significant reductions in metastases [5] - A single systemic dose of SIL204 maintained effective drug levels for over 56 days, indicating potential for long-term therapeutic exposure [5] - An expanded dual-route development strategy for SIL204 was unveiled, integrating systemic and intratumoral administration to target both primary tumors and metastatic progression [5] - A strategic collaboration with Catalent was announced to conduct formulation development and clinical manufacturing activities for SIL204 [5] Financial Results Highlights - Cash and cash equivalents increased to $6.2 million as of March 31, 2025, from $1.2 million as of December 31, 2024, primarily due to successful financing activities [10] - Total operating expenses for Q1 2025 were $1.7 million, compared to $1.3 million in Q1 2024, with research and development expenses decreasing to $0.6 million [6][10] - The net loss for Q1 2025 was $1.7 million, compared to $1.4 million for the same period in 2024, attributed to higher general and administrative expenses [10][14]

Arrowhead Pharmaceuticals (ARWR) Q2 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince. Speaker1 Thank you, and good afternoon, everyone. S ...

Core Insights - Sibylla Biotech has appointed Dieter Weinand as Chairman of its Board of Directors, bringing over 35 years of experience in the pharmaceutical sector [1][4] - The company aims to advance its innovative PPI-FIT technology and pipeline of folding interference small molecules to address challenging therapeutic areas [1][3] Company Overview - Sibylla Biotech is focused on transforming drug discovery by targeting protein folding intermediates, which represents a new druggable dimension in pharmacology [6] - The proprietary PPI-FIT technology allows the company to predict and target intermediate steps in the protein folding process, leading to targeted protein degradation [6][7] Leadership Background - Dieter Weinand has a distinguished career, having held significant roles at major pharmaceutical companies such as Bayer Pharmaceuticals AG, Sanofi, Bristol-Meyers Squibb, and Pfizer [4][5] - His leadership experience includes overseeing the integration of R&D, manufacturing, and commercial functions, contributing to the launch of several high-impact medicines [4] Strategic Vision - The appointment of Mr. Weinand is seen as a strategic move to unlock access to previously undruggable targets and drive the next stages of Sibylla's growth [2][3] - The company is building a pipeline of treatments for high medical need diseases across multiple therapeutic areas, with a mission to bring protein folding interference therapeutics to patients [7]

Core Insights - Silexion Therapeutics has announced a strategic collaboration with Catalent to advance its RNA interference (RNAi) cancer therapies, specifically targeting KRAS-driven cancers [1][4] - The collaboration will focus on the formulation development and clinical manufacturing of Silexion's siRNA candidate, SIL204, at Catalent's facility in Limoges, France [2][4] - Silexion aims to initiate human clinical trials for SIL204 in the first half of 2026, following promising preclinical results [4][5] Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNAi therapies for solid tumors driven by KRAS mutations, which are prevalent in various cancers [6] - The company's first-generation product, LODER™, has shown promising results in Phase 2 trials for non-resectable pancreatic cancer [6] - SIL204 is designed to target a broader range of KRAS mutations and has demonstrated significant efficacy in preclinical studies [3][6] Collaboration Details - Catalent will optimize both systemic and intratumoral delivery formulations of SIL204, supporting Silexion's dual-route development strategy [2][4] - The collaboration leverages Catalent's expertise in complex formulation development to enhance SIL204's stability, bioavailability, and delivery precision [4] - Silexion plans to conduct additional toxicology and pharmacodynamic studies throughout 2025, with regulatory submissions anticipated in late 2025 and early 2026 [5]

Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the PresentationGrand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies fo ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 近日，专注于无创深脑神经调控技术的 西安穹顶医疗科技有限公司 成功完成 数千万元 A轮融资 。本轮融 资由 华方资本 与 讯飞创投 共同领投， 合盈资本 跟投， 行远致同 担任独家财务顾问。 资金将用于加速时间干涉技术（Temporal Interference，TI）在脑科学领域的探索，推动多场景产品方案 的临床注册、产品获证及商业化落地。 # 公司介绍 穹顶医疗成立于2019年11月，总部位于西安。公司专注于无创深脑神经调控技术的研发与应用，是该领域 的创新引领者。穹顶医疗深耕无创神经调控领域近10年，已掌握并实现人体TI无创深脑精准神经调控。公 司拥有60余项发明专利和实用新型专利，产品线涵盖科研与临床应用。 产 品与技术介绍 穹顶医疗的核心技术为时间干涉技术（TI），该技术通过高频电流在脑深部形成低频电场"包络"，实现无 创、深脑、高精度、多靶点的神经调控。公司的第六代产品TIs EMO-1000/TIs CAP具备高精度刺激控制 功能，可输出不 ...